<DOC>
	<DOCNO>NCT00412022</DOCNO>
	<brief_summary>The HOBOE study amend November 2009 , , reach enrollment first 500 patient , study begin recruit premenopausal patient . The primary objective extend study compare disease free survival premenopausal patient early breast cancer . Patients receive triptorelin randomize 1:1:1 fashion receive tamoxifen letrozole , letrozole + zoledronic acid . The purpose HOBOE study , Version 1 , compare adjuvant hormonal therapy treatment Tamoxifen , Letrozole Letrozole + Zoledronate effect bone loss breast cancer patient . Postmenopausal premenopausal patient eligible , latter also receive monthly triptorelin . Upon reach enrollment first 500 patient March 2010 , study begin recruit premenopausal patient .</brief_summary>
	<brief_title>HOBOE : A Phase 3 Study Adjuvant Triptorelin Tamoxifen , Letrozole , Letrozole Zoledronic Acid Premenopausal Patients With Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histological diagnosis breast cancer Surgical resection breast cancer ( breast conserve surgery mastectomy ) No evidence disease Indication adjuvant hormonal therapy ( ER and/or PgR positive IHC exam least 1 % primary tumor cell , accord St. Gallen criterion ) Patient age least 18 year Written inform consent . Premenopausal status define LMP within 12 month randomization ( FSH , LH consider determinant menopausal status due chemotherapy induce reversible ovarian suppression ) Please note patient receive neoadjuvant adjuvant chemotherapy and/or locoregional radiation therapy may include study Performance status ( ECOG ) &gt; 2 . Previous concomitant malignancy ( exception adequately treat nonmalignant skin cancer carcinoma situ uterine cervix Metastatic breast cancer Creatinine &gt; 1.25 time value upper normal limit Pregnant lactating female Clinical radiologic evidence bone fracture Treatment systemic cortisone therapy within 12 month prior randomization Treatment drug could alter bone metabolism ( calcitonin , mithramycin , gallium nitrate ) within 2 week prior randomization Previous treatment tamoxifen aromatase inhibitor AST and/or ALT &gt; 3 time value upper normal limit clinical laboratory finding indicate grade hepatic insufficiency could potentially increase risk assume letrozole Any concomitant condition would , Investigator 's opinion , contraindicate use drug use study Inability provide inform consent Inability comply followup Patient undergo invasive dental work time baseline evaluation foreseen course adjuvant therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>early breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>premenopause</keyword>
	<keyword>premenopausal</keyword>
	<keyword>menopausal status</keyword>
	<keyword>postmenopause</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>hormone sensitive</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>disease-free survival</keyword>
</DOC>